Module Innovations, Pune, India
URINARY TRACT INFECTIONS (UTI)
Diagnostic and antibiotic susceptibility test
A UTI is an infection of the bladder, kidneys, ureters, or urethra that occurs when bacteria enter the urinary system. There are an estimated 150 million UTI cases globally each year, disproportionately affecting women. Increasingly, UTIs involve drug-resistant bacteria. Module Innovations is developing a simple cost-effective easy-to-use diagnostic and antibiotic susceptibility test (ID/AST) that will produce results and provide the antibiotic resistance profile of the pathogen within two hours, rather than days. The test is designed to be particularly useful in low- and middle-income countries. A urine sample would be loaded into the ASTSENSe device, which would diagnose the infection quickly and provide vital information on which antibiotics would be effective against the superbug, including deadly common uropathogens such as Escherichia coli, Klebsiella, Pseudomonas aeruginosa and Enterococci faecalis that often cause infection. UTIs can be deadly. An estimated 13,000 people die each year in the US alone from urinary tract infections.
Current Development Stage: Feasibility
CARB-X Investment: Initial investment of up to $702,000 with potential option payments up to $2.5m.
Initial CARB-X Investment Date: March 1, 2020